Identification of Biomarkers Associated With Pathological Stage and Prognosis of Clear Cell Renal Cell Carcinoma by Co-expression Network Analysis
暂无分享,去创建一个
Chin-Lee Wu | Kaiyu Qian | Han C. Dan | Xinghuan Wang | Lushun Yuan | Liang Chen | Yu Xiao | Guofeng Qian | Yuan Zhu
[1] S. Hancock,et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] Xinghuan Wang,et al. Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma , 2017, International journal of biological sciences.
[3] Pengfei Chen,et al. Co-expression network analysis identified six hub genes in association with metastasis risk and prognosis in hepatocellular carcinoma , 2017, Oncotarget.
[4] Yunfeng Zhou,et al. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis , 2017, Oncotarget.
[5] B. Dai,et al. Identification and validation of an eight‐gene expression signature for predicting high Fuhrman grade renal cell carcinoma , 2017, International journal of cancer.
[6] A. Belldegrun,et al. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.
[7] Wenquan Zhou,et al. Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. , 2015, International journal of clinical and experimental pathology.
[8] Haifei Xu,et al. Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. , 2015, International journal of clinical and experimental pathology.
[9] S. Horvath,et al. Single-Cell Transcriptome Analyses Reveal Signals to Activate Dormant Neural Stem Cells , 2015, Cell.
[10] J. Choudhary,et al. Identification of protein complexes that bind to histone H3 combinatorial modifications using super-SILAC and weighted correlation network analysis , 2015, Nucleic acids research.
[11] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[12] D. Radisky,et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. , 2014, Cancer research.
[13] Chun-Yu Chuang,et al. Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer , 2014, BMC Genomics.
[14] S. Cha,et al. VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma , 2014, Journal of lifestyle medicine.
[15] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[16] L. O’Driscoll,et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. , 2013, Carcinogenesis.
[17] N. Grishin,et al. BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.
[18] T. Wilt,et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials , 2011, BJU international.
[19] Rui Luo,et al. Is My Network Module Preserved and Reproducible? , 2011, PLoS Comput. Biol..
[20] C. Farber. Identification of a gene module associated with BMD through the integration of network analysis and genome‐wide association data , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] M. Goel,et al. Understanding survival analysis: Kaplan-Meier estimate , 2010, International journal of Ayurveda research.
[22] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[23] C. Porta,et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. , 2010, European journal of cancer.
[24] S. Horvath,et al. Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways , 2010, Proceedings of the National Academy of Sciences.
[25] P. Bühlmann,et al. Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.
[26] Steve Horvath,et al. A Systems Genetics Approach Implicates USF1, FADS3, and Other Causal Candidate Genes for Familial Combined Hyperlipidemia , 2009, PLoS genetics.
[27] R. Motzer,et al. Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.
[28] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[29] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[30] G. Church,et al. Systematic determination of genetic network architecture , 1999, Nature Genetics.
[31] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[32] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[33] S. Hancock,et al. Kidney cancer, version 3.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[34] P. Cairns. Renal cell carcinoma. , 2010, Cancer biomarkers : section A of Disease markers.
[35] A. Ravaud,et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.
[36] Xianrang Song,et al. Maturation of a central , 1996 .
[37] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.
[38] John D. Storey,et al. Supplementary Text: Capturing Heterogeneity in Gene Expression Studies Nested Ks-tests: a Procedure to Test Whether a Procedure Is Valid , 2022 .